Shrilekha Misra

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment”.

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment

Oncotarget(2020)10.18632/oncotarget.27485

N/A

0DataRank · unranked

12 citations

Xiaoli Zhang, Nissar Ahmad Wani, Steven T. Sizemore, Alo Ray, Shrilekha Misra

Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients

Blood(2022)10.1182/blood.2021015132

N/A

0DataRank · unranked

11 citations

Xiaomeng Huang, 義行高橋, Szabolcs Tarapcsák, Kerry A. Rogers, Shrilekha Misra +5 more